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tract infections (45% cases), skin and soft tissue infections, meningitis). For decades the genus 
Acinetobacter has undergone several taxonomical modifications. In the last few years these 
organisms are genetically modifying into highly resistant forms resulting in untreatable 
nosocomial infections and health care associated infections. A. baumannii can cause severe or 
fatal illnesses, especially in critically ill patients with low immune responses, and can increase 
patient mortality along with hospital costs.  Studies show that the mortality rate of hospitalised 
patients infected with A. baumannii is 8-23%, and 10-43% at intensive care units. 
Aim of the study. Determining the degree of spread of nosocomial infections caused by 
Acinetobacter spp., nosological structure, epidemiological features, antibiotic resistance. 
Materials and methods.  A descriptive cross-sectional study was conducted for 2014–2016 
on the model of the Republican Clinical Hospital, the Institute of Neurology and Neurosurgery, 
and the Institute of Emergency Medicine. 
Results.  In 2014-2016, in the three hospitals mentioned above, 1,005 cases of purulent-septic 
infections caused by Acinetobacter spp. were investigated. Most often they are found in 
intensive care units, anesthesiology and intensive care (56.32%), surgery (15.72%) and 
traumatology and orthopedic (14, 82%).  The largest share is occupied by A. baumannii 
(98.69%), compared with A. iwoffii (0.95%) and A. haemolyticus (0.36%). Acinetobacter 
strains are mainly found in monocultures (65.77%), but in 34.23% - in associations in which 
gram-negative microorganisms significantly prevail (79.86%), including P. aeruginosa 
(33.49%), K pneumoniae (17.33%) and E. coli (11.48%).  In 81.13%, Acinetobacter strains are 
resistant to antibiotics, and only 18.87% are sensitive to them. Acinetobacter strains were more 
resistant to penicillins (97.02%), penicillins + beta-lactamase inhibitors (96.73%), 
cephalosporins I generation (99.40%), cephalosporins II generation (98.86%), cephalosporins 
III generations (97.44%), IV generation cephalosporins (93.88%), nitrofurans (98.97%), 
macrolides (94.38%). A higher sensitivity is manifested in the following groups of antibiotics: 
cyclic polypeptides (94.42%), tetracyclines (85.12%) and other antibacterial agents (50.96%). 
Conclusions.  Most infections caused by Acinetobacter baumannii have been detected in 
patients hospitalized in intensive care units and surgical departments. Acinetobacter baumannii 
is resistant to most antibiotics, and sensitivity to the currently used antibiotics is significantly 
reduced. High prevalence of antibiotic-resistant strains of Acinetobacter spp. emphasizes the 
importance of the use of selective antibiotic therapy and the strict monitoring of measures to 
combat nosocomial infections. 
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Introduction. Vaccination is the most effective means of influenza prevention. The current 
epidemiological influenza situation in the world indicates that trivalent vaccines are not able to 
protect the population from all circulating strains of type B influenza virus, that necessitates 
the improvement and expansion of the composition of the vaccines.  
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Aim of the study. To evaluate the immunogenicity of influenza tetravalent inactivated subunit 
adjuvant vaccine in healthy adults and in patients with common variable immune deficiency.  
Materials and methods. In a single-center, open-label, non-randomized, prospective, cohort, 
controlled study before the flu season 2018-2019 were involved 32 healthy volunteers aged 18-
50 years and the comparison group which consisted of 6 patients with a confirmed diagnosis 
of common variable immune deficiency (CVID). All patients received 1 dose (0,5 ml) of the 
first Russian quadrivalent inactivated subunit vaccine (IIV4) with a decreased amount 
hemagglutinin protein (20 mkg of influenza H-antigens instead of 60 mkg in standart non-
adjuvant IIV4 in the world) due to the use of azoximer bromide (500 mkg per dose). The 
antibody levels against the influenza type A viruses (H1N1 and H3N2) and two type B viral 
cell lines (B/Yamagata and B/Victoria) were evaluated using a hemagglutination inhibition 
reaction. The seroprotection, seroconversion, geometric mean titer rates, CD-subpopulations 
(CD3+, CD4+, CD8+, CD16,56+, CD19+, CD21+) and expression of toll-like receptors 3, 8, 
9 were analized.  
Results. Adjuvant IIV4 in healthy adults elicited comparable immune response for matched 4 
influenza strains with explored non-adjuvant IIV4 in the world. Patients with common variable 
immune deficiency failed to form a protective humoral immune response to adjuvant IIV4 
although CD-subpopulations and expression of toll-like receptors 3, 8, 9 were similar to healthy 
controls that may indirectly indicate the possibility of the formation of cellular immunity in 
response to vaccination in these patients.  
Conclusions. The use of adjuvant IIV4 allows to form protection against 2 circulating 
influenza B lineages without reduction of the immunogenicity in relation to influenza strains 
type A. To evaluate the effectiveness of the influenza vaccine in patients with PID it is 
necessary to study other mechanisms of the development of a postvaccinal immune response.  
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Introduction. Tourism is an important socioeconomic phenomenon in continuous 
development. Every traveler is exposed to nearly all infectious risks which may occur during 
his travel time. Some of the main risk factors can be temperature, water quality, high humidity 
and the exposure to multi-resistant microorganisms. However, studies suggest that very few 
people seek health advice prior to travel.  
Aim of the study. This study was conducted to determine the level of knowledge, attitudes and 
practices of medical students in the field of travel medicine.  
Materials and methods. A cross-sectional study was conducted between October and 
November 2019, using a self-administered questionnaire. The 345 students who took part in 
this study were enrolled in 5th or 6th year of general medicine program, in different medical 
centers from Romania and they have traveled abroad at least once in their lifetime. The data 
were analyzed using the statistical program SPSS (Statistical Package for Social Sciences). We 
used the Chi square test to identify differences in knowledge, attitudes and practices between 
students. Differences with a value of p ≤ 0.05 were considered statistically significant.  
